Effect of Screening on Ovarian Cancer Mortality

Author:

Top Cited Papers
Open Access
Abstract
In the United States, ovarian cancer is among the 5 leading causes of cancer death in women.1 The high case-fatality ratio of ovarian cancer may be attributed in part to its vague and nonspecific symptoms, which usually appear when the disease has reached an advanced stage. Ovarian cancer confined to the ovary has a 5-year survival of 92%. However, most women with ovarian cancer are diagnosed with advanced stage disease, which has a 5-year survival of only 30%.1 The recognition that early detection of ovarian cancer may have the potential to improve prognosis prompted the development of randomized controlled trials, including the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, to evaluate the efficacy of transvaginal ultrasound and serum cancer antigen 125 (CA-125) as screening tools to reduce ovarian cancer mortality.2-4

This publication has 18 references indexed in Scilit: